¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2021-09-03

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2021-09-03
±³À°ÀÏÀÚ : 2021-09-03
±³À°Àå¼Ò : ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ ¹× ´ëȸÀǽǠ 
±³À°ÁÖÁ¦ : ´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À°
ÁÖÃÖ±â°ü : ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑ¿ì¿ï.Á¶¿ïº´ÇÐȸ (ÀÌ»çÀåÁ¦)  
´ã´çÀÚ : ´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ »ç¹«±¹
¿¬¶ôó : 02-3779-1250  
À̸ÞÀÏ : webmaster@thekasad.or.kr      
±³À°Á¾·ù : Á¤½Å°Ç°­ÀÇÇаú      
Âü¼®¿¹»óÀοø : 90¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 13 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í »çÀüµî·Ï: Á¤È¸¿ø 5¸¸¿ø, ÁØȸ¿ø 3¸¸¿ø, ºñȸ¿ø 6¸¸¿ø, Æò»ýȸ¿ø ¸éÁ¦ ´çÀϵî·Ï: Á¤È¸¿ø 6¸¸¿ø, ÁØȸ¿ø 4¸¸¿ø, ºñȸ¿ø 8¸¸¿ø, Æò»ýȸ¿ø 1¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 09:30~09:50 Mood and personal traits as risk factors for physical illness  È«Á¤¿Ï(Àͻ꺴¿ø) 
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 09:50~10:10 Inflammation, physical illness, and depression  ½Å»óÈ£(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 10:10~10:40 Metabolic syndrome and bipolar disorder  °­¿ø¼·(°æÈñÀÇ´ë) 
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 10:55~11:15 Antidepressants: Minimalist vs. maximalist view  ¹Ú¼º¿ë(°è¿äº´¿ø) 
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 11:15~11:35 Antipsychotics: Evidence based treatment vs. potential treatment  ¹Ú¿µ¹Î(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 11:35~12:05 Augmentation therapy: Focus on dopamine agonist & stimulant  Á¤¸íÈÆ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 12:05~12:35 Anxiety & depression in the COVID pandemia  ¿ì¿µ¼·(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 12:35~13:05 Benefits of Agomelatine treatment strategies  Á¤Á¾Çö(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 13:20~13:35 ¡®Irritability¡¯ as a symptom of depression for children and adolescents?  À̹®¼ö(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 13:35~13:50 What can tell the differences between bipolar disorder and ADHD?  ½É¼¼ÈÆ(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 13:50~14:05 Are there cognitive dysfunctions in bipolar disorder?  ¿Õ¼º¹Î(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 14:05~14:30 What is the vascular depression hypothesis?  ÀÌ°­¼ö(Â÷ÀÇ°úÇдë) 
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 14:30~14:50 Major depressive disorder  ¿ì¿µ¼·(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 14:50~15:10 Bipolar disorder: Manic episode and mixed features  ¹®Àº¼ö(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 15:10~15:40 Bipolar disorder: Depressive episode  ÀÓÀº¼º(½Å¼¼°èÈ¿º´¿ø) 
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 15:50~16:10 Navigating the world of ADHD medications  ¾çÂù¸ð(¿ø±¤ÀÇ´ë) 
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 16:10~16:30 Diagnosing and treating major depressive episodes with mixed features  ½ÉÀÎÈñ(µ¿³²±Ç¿øÀÚ·ÂÀÇÇпø) 
±³À°½Ã°£ 09-03 ÄÁº¥¼ÇȦ 16:30~17:00 Long-acting injectable antipsychotics in bipolar disorder  ±è°æ¹Î(±¹¸³³ªÁÖº´¿ø) 
±³À°½Ã°£ 09-03 ´ëȸÀǽǠ09:30~09:50 Suicide rate and risk factors in pandemic  °­ÇÑ°íÀººñ(±¹¸³³ªÁÖº´¿ø) 
±³À°½Ã°£ 09-03 ´ëȸÀǽǠ09:50~10:10 Immunity, suicide and COVID-19: A linking pathway  Àå½ÂÈ£(¿ø±¤ÀÇ´ë) 
±³À°½Ã°£ 09-03 ´ëȸÀǽǠ10:10~10:40 Suicide prevention during COVID-19  ¿ÀÈ«¼®(°Ç¾çÀÇ´ë) 
±³À°½Ã°£ 09-03 ´ëȸÀǽǠ10:55~11:55 Mindfulness-based interventions for depression  ±¸º»ÈÆ(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 09-03 ´ëȸÀǽǠ12:05~12:35 Importance of multifactorial condition management  ¼ºÇü¸ð(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 09-03 ´ëȸÀǽǠ12:35~13:05 Successful management of patient adherence  ³²¹ü¿ì(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 09-03 ´ëȸÀǽǠ13:20~13:40 Glutamatergic system  ¼Û¹Î±Ô(¼º¸ð°ø°¨Á¤½Å°Ç°­ÀÇÇаúÀÇ¿ø) 
±³À°½Ã°£ 09-03 ´ëȸÀǽǠ13:40~14:00 GABAergic system  ±èÅÂÈñ(¿¬¼¼¿øÁÖÀÇ´ë) 
±³À°½Ã°£ 09-03 ´ëȸÀǽǠ14:00~14:30 Inflammatory system  ÀÌÁ¤±¸(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 09-03 ´ëȸÀǽǠ14:30~15:00 Overview and CBT approaches  ±è¿ø(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 09-03 ´ëȸÀǽǠ15:00~15:30 Family interventions  Á¤¿µÀº(Á¦ÁÖÀÇ´ë) 
±³À°½Ã°£ 09-03 ´ëȸÀǽǠ15:50~16:10 PTSD and depression after trauma exposure  À̺´Ã¶(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 09-03 ´ëȸÀǽǠ16:10~16:30 Biological underpinnings of trauma and depression  ±èÁö¼±(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 09-03 ´ëȸÀǽǠ16:30~17:00 Treating depression of victims  ±è¿øÇü(ÀÎÇÏÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2021-09-03""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѺñ¸¸ÇÐȸ ICOMES 2021 (2ÀÏÂ÷) : 2021-09-03
´ÙÀ½±Û ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ (¿Â¶óÀÎ) International Colorectal Research Summit 2021-Precongress (1ÀÏÂ÷) : 2021-09-03
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20805 ¼­¿ï 2024 ´ëÇÑ»ê°ú¸¶ÃëÇÐȸ Á¦27Â÷ Çмú´ëȸ : 2024-06-15 0 6 2024-05-27
20804 ÃæºÏ 204 ÃæûºÏµµÀÇ»çȸ Ãá°è Çмú´ëȸ : 2024-06-15 0 9 2024-05-27
20803 ºÎ»ê 2024³â Á¦7ȸ ´ëÇÑÁßȯÀÚÀçÈ°ÇÐȸ Áý´ãȸ : 2024-06-15 0 6 2024-05-27
20802 ºÎ»ê 2024³â ´ëÇÑÁßȯÀÚÀçÈ°ÇÐȸ ¿öÅ©¼¥-±â´ÉÀû Æò°¡ ¹× ÁßȯÀÚ ÀçÈ°ÀÇ ½ÇÁ¦ (¿Ü»ó ÁßȯÀÚ Æ÷ÇÔ) : 2024-06-15 0 8 2024-05-27
20801 ¼­¿ï KLASS 20Áֳ⠱â³ä 2024 ´ëÇѺ¹°­°æÀ§Àå°ü¿¬±¸È¸ Á¦27ȸ Á¤±âÇмú´ëȸ : 2024-06-15 0 7 2024-05-27
20800 °æ±â 2024³â Á¦ 3ȸ Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-15 0 14 2024-05-27
20799 ¼­¿ï (¿Â¶óÀÎ) 2024³âµµ ÀÓ»óÁø·áÁöħ Æò°¡À§¿ø ¾ç¼º±³À° : 2024-06-15 0 7 2024-05-27
20798 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼҾÆû¼Ò³â°ú ºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À° : 2024-06-15 0 3 2024-05-27
20797 ¼­¿ï ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ COPD School 2024 : 2024-06-15 0 7 2024-05-27
20796 ¼­¿ï »óóÀå·ç¿¬±¸È¸ Áý´ãȸ : 2024-06-15 0 5 2024-05-27
20795 Àü³² 2024³â Àü¶ó³²µµÀÇ»çȸ Àü¹Ý±â Çмú´ëȸ : 2024-06-15 0 8 2024-05-27
20794 ¼­¿ï Ç÷°ü¿µ»ó»ý¸®¿¬±¸È¸ IPOP(Imaging and Physiology on Patients with Cardiovascular Disease) 2024 : 2024-06-15 0 4 2024-05-27
20793 ¼­¿ï ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ ¾à¹°¾Ë·¹¸£±â ½ÉÆ÷Áö¾ö : 2024-06-15 0 10 2024-05-27
20792 ´ëÀü ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ´ëÀü, ÃæûÁöȸ - Á¦3Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-15 0 4 2024-05-27
20791 ¼­¿ï Á¦51ȸ ´ëÇÑÀÓ»óÇǺÎÄ¡·á¿¬±¸È¸ ±³À°½ÉÆ÷Áö¾ö : 2024-06-15 0 7 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷